QR-Code

Safety and Immunogenicity of the Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults: Results from a Phase 2, Randomized, Controlled, Dose-Finding Trial with Long-Term Extension Follow-Up Through Month 48

<b>Background/Objectives:</b> No licensed vaccine against cytomegalovirus (CMV) is currently available, despite the significant risk of mother-to-infant transmission leading to serious neurodevelopmental impairment and the substantial morbidity caused by CMV infection in immunocompromised persons. W...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Carlos Fierro, Daniel Brune, Richard Leggett, James Peterson, Benjamin Lorenz, Renato Calabro Calheiros, Jiang Lin, Anita S. Iyer, Kai Wu, Xin Cao, Alaknanda Kondapally, Sheila Marsh, Shiva Kalidindi, Jennifer Husson, Lori Panther
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2026-05-01
Schriftenreihe:Vaccines
Schlagworte:
cytomegalovirus
CMV
congenital cytomegalovirus
cCMV
clinical trial
immunogenicity
Online-Zugang:https://www.mdpi.com/2076-393X/14/5/444
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge